$0.47
(Market cap
$3,805 Mln
Recently Viewed
Clear AllMarket cap
$3,805 Mln
Revenue (TTM)
$1,072 Mln
P/E Ratio
9.7
P/B Ratio
3.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
25.9
Debt to Equity
0
Book Value
$7.2
EPS
$2.3
Face value
--
Shares outstanding
170,494,613
CFO
$-1,294.25 Mln
EBITDA
$-2,046.04 Mln
Net Profit
$-2,024.88 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals (ACAD)
| -15.5 | 1.8 | -17.7 | 54.4 | 7.1 | 1.2 | -3.5 |
|
BSE Sensex*
| -9.5 | -2.9 | -9.0 | 3.2 | 8.6 | 9.0 | 12.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals (ACAD)
| 45.6 | -41.1 | 96.7 | -31.8 | -56.3 | 25.0 | 164.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals (ACAD)
|
22.6 | 3,805.4 | 1,071.5 | 391.0 | 9.0 | 39.9 | 9.7 | 3.1 |
| 64.4 | 8,558.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.2 | 15.0 | |
| 233.2 | 13,917.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 65.8 | 7,998.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 44.2 | 11,791.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 92.8 | 11,760.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 519.8 | 12,247.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 520.7 | 14,077.1 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.5 | 30.8 | |
| 105.0 | 8,153.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 320.2 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse... agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. Address: 12830 El Camino Real, San Diego, CA, United States, 92130 Read more
President, CEO & Director
Mr. Stephen R. Davis J.D.
President, CEO & Director
Mr. Stephen R. Davis J.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ACADIA Pharmaceuticals Inc (ACAD) is $22.56 (NASDAQ) as of 08-Apr-2026 16:00 EDT. ACADIA Pharmaceuticals Inc (ACAD) has given a return of 7.13% in the last 3 years.
The P/E ratio of ACADIA Pharmaceuticals Inc (ACAD) is 9.70 times as on 07-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
11.71
|
3.73
|
|
2024
|
13.48
|
4.17
|
|
2023
|
-85.07
|
12.07
|
|
2022
|
-11.94
|
6.44
|
|
2021
|
-22.37
|
6.94
|
The 52-week high and low of ACADIA Pharmaceuticals Inc (ACAD) are Rs 28.35 and Rs 13.40 as of 09-Apr-2026.
ACADIA Pharmaceuticals Inc (ACAD) has a market capitalisation of $ 3,805 Mln as on 07-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in ACADIA Pharmaceuticals Inc (ACAD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.